Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Expanded Access Guidances Fail To Achieve Détente With Advocates

Executive Summary

The number of requests to use investigational drugs outside of clinical trials has grown and FDA typically approves all requests, but advocates still insist the process is set up to fail patients.


Related Content

FDA Can't Win On Guidances: Expanded Access Policy, Duchenne Worries Collide
Expanded Access INDs: FDA’s Near-Perfect Approval Rate Underscores Problems, Advocates Say
FDA “Breakthrough” Designation Bill Revives Debate About Legislating Flexibility
BIO Wants Expanded Accelerated Approval In PDUFA Instead Of Progressive Approval
Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy
Making Expanded Access Programs Work For - Not Against - Your Trial Drug
Access To Investigational Drugs Remains Challenge Despite New FDA Rules
FDA Rules On INDs May Embolden More Patients To Ask For Trial Drugs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts